Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospitalised with COVID-19. The trial met its primary endpoint, showing that Ronapreve significantly reduced viral load within seven days of treatment in patients who had not mounted a natural antibody response of their own (seronegative) and who required low-flow or no supplemental oxygen (p=0.0172).
Phase II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantly reduces viral load in patients hospitalised with COVID-19
September 30, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022